Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq in SMARCD2 k/d NB4 cells with/without ATRA differentiation

ABSTRACT: We report differential gene expression in the human AML cell line NB4 that can be partially differentiated into neutrophil granulocytes by 1µM ATRA for 2d or the vehicle DMSO only ((mock))

ORGANISM(S): Homo sapiens

PROVIDER: GSE93877 | GEO | 2017/01/20

SECONDARY ACCESSION(S): PRJNA362639

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome wide DNA accessibility screen by ATAC-Seq in SMARCD2 k/d NB4 cells with/without ATRA differentiation

Project description:We report differential chromatin accessiblity in the human AML cell line NB4 that can be partially differentiated into neutrophil granulocytes by 1µM ATRA for 2d or the vehicle DMSO only ((mock))

2017-01-20 | GSE93876 | GEO

Gene expression profiling of ATRA-differentiated wild-type and TG2 knockout NB4 cells

Project description:Treatment of acute promyelocytic leukemia (APL) with all-trans-retinoic acid (ATRA) results in terminal differentiation of leukemic cells toward neutrophil granulocytes. Administration of ATRA leads to massive changes in gene expression, including down-regulation of cell proliferation-related genes and induction of genes involved in immune function. One of the most induced genes in APL NB4 cells is transglutaminase 2 (TG2). RNAi-mediated stable silencing of TG2 in NB4 cells (TG2-KD NB4) coupled with whole genome microarray analysis revealed that TG2 is involved in the expression of a large number of ATRA-regulated genes. The affected genes participate in granulocyte functions and their silencing lead to reduced adhesive, migratory and phagocytic capacity of neutrophils and less superoxide production. The expression of genes related to cell cycle control also changed, suggesting that TG2 regulates myeloid cell differentiation. CC chemokines CCL2, 3, 22, 24 and cytokines IL1B and IL8 involved in the development of differentiation syndrome (DS) are expressed at significantly lower levels in TG2-KD NB4 cells than in wild-type NB4 cells upon ATRA treatment. Based on our results, we propose that reduced expression of TG2 in differentiating APL cells may suppress effector functions of neutrophil granulocytes and attenuate the ATRA-induced inflammatory phenotype of DS. We used microarrays to detail the global program of gene expression underlying ATRA-induced differentiation of TG2 knockout NB4 cells. TG2 knockout NB4 cells were differentiated for 48 and 72 hours in the presence of ATRA and their gene expression profiles were compared to the wild-type cells at the same time points. Undifferentiated wild-type and TG2 knockout NB4 cells were used as untreated controls. Three biological replicates each.

2010-12-01 | E-GEOD-23702 | biostudies-arrayexpress

Gene expression profiling of ATRA-differentiated wild-type and TG2 knockout NB4 cells

2010-12-01 | GSE23702 | GEO

Expression profiling of ATRA treated NB4 cells

Project description:NB4 is an APL derived cell line, carrying the t(15;17) translocation and expressing the PML/RARa fusion protein. Still, an important question that remains to be addressed is whether PML/RARa target genes are transcriptionally suppressed in primary APL cells and re-activated in all-trans retinoic acid (ATRA) treated NB4 cells. Gene expression of NB4 cells treated with ATRA at different time points were analyzed.

2009-11-26 | GSE19201 | GEO

Transcription profiling of human ATRA treated NB4 cells

2009-12-14 | E-GEOD-19201 | biostudies-arrayexpress

Proteome dynamics of HL-60, NB4, and K562 cells under the ATRA treatment

Project description:Searching for new strategies of acute myeloid leukemia (AML) treatment is of particular interest. Cell lines, e. g. HL-60 and NB4, represent model systems to study molecular features of leukemic cells. The all-trans-retinoic acid (ATRA) has proven itself to be an effective treatment for one of AML subtypes, i.e., acute promyelocytic leukemia (APL). At the same time, ATRA causes granulocytic differentiation of non-APL leukemic cells in vitro. Combination of new therapeutics with ATRA could improve efficiency of treatment. Studying the proteome perturbation in leukemic cells under the ATRA treatment allows to determine potential regulatory molecules that could be affected pharmacologically. Thus, the TMT-based proteomic profiles of HL-60, NB4, and K562 cell lines under the ATRA treatment were obtained at 0, 3, 12, 24, and 72 h after the ATRA treatment.

2024-06-23 | PXD050317 | Pride

Effect of ATRA on HH, Hut78 and NB4 cells

Project description:Cutaneous T-cell lymphoma (CTCL) is a highly heterogeneous non-Hodgkin lymphoma.While retinoids analog including ATRA have been used to treat CTCLs for decades, their mechanism of action and the role of RA-RARα signaling remain poorly understood.Thus,we treated CTCL cells with ATRA.In parallel, we treated acute promyelocytic leukemia (APL) cell line NB4 with ATRA followed by RNA-seq analysis.Total RNA was prepared from biological duplicate plates of cells and subjected to bulk RNAseq. 150-bp paired-end sequencing was performed on the BGISEQ-500.

2024-04-01 | GSE262586 | GEO

Transcription profiling by array of ATRA- and control-treated NB4 leukemia cells

Project description:The acute promyelocytic leukemia-derived cell line, NB4, was grown at 37°C in 5% CO2 in an RPMI medium supplemented with 2 mM L-glutamine and 10% decomplemented fetal calf serum. Cells were cultured for 48 h with or without 1 μM All-trans retinoic acid (ATRA). Duplicates of 3 independent experiments were analyzed.

2015-02-26 | E-MTAB-3369 | biostudies-arrayexpress

Effect of ATRA on HH, Hut78 and NB4 cells

Project description:Effect of ATRA on HH, Hut78 and NB4 cells

| PRJNA1092602 | ENA

RNA-Seq and ATAC-Seq in SMARCD2 k/d NB4 cells with/without ATRA differentiation

Project description:RNA-Seq and ATAC-Seq in SMARCD2 k/d NB4 cells with/without ATRA differentiation

| PRJNA362635 | ENA